Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

A Study of Risvutatug Rezetecan in Combination With Atezolizumab in Participants With Extensive Stage Small Cell Lung Cancer (EMBOLD-SCLC-303)

12. November 2026 aktualisiert von: GlaxoSmithKline

A Phase 3 Randomized Open-Label Study to Evaluate the Safety and Efficacy of Risvutatug Rezetecan in Combination With Atezolizumab in Participants With Newly Diagnosed Extensive Stage Small Cell Lung Cancer

Extensive-stage small cell lung cancer (ES-SCLC) is an aggressive type of lung cancer. Current treatment options are limited, and response to treatment may not last long. Outcomes are especially poor when the cancer has spread to the brain. This study tests whether a new treatment: risvutatug rezetecan (Ris-Rez) with atezolizumab works better than standard of care treatment. Ris-Rez is designed to deliver cancer-killing medicine directly to cancer cells. Atezolizumab helps the immune system attack cancer cells. Researchers will see if this combination helps people live longer and keeps the cancer from getting worse.

Studienübersicht

Status

Noch keine Rekrutierung

Bedingungen

Intervention / Behandlung

Studientyp

Interventionell

Einschreibung (Geschätzt)

700

Phase

  • Phase 3

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studieren Sie die Kontaktsicherung

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Is at least 18 years of age or the legal age of consent in the jurisdiction in which the study is taking place at the time of signing the informed consent form (ICF).
  • Has histologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC) at initial diagnosis and at trial entry and has received no prior systemic therapies for SCLC, with 1 exception where participants who have received one cycle of etoposide and carboplatin with or without atezolizumab are eligible
  • Is capable of giving signed informed consent including compliance with the requirements and restrictions listed in the ICF and protocol.
  • Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Has adequate organ function.

Exclusion Criteria:

  • Has symptomatic central nervous system (CNS) metastases, CNS metastases with hemorrhagic features, or leptomeningeal disease.
  • Has known allergy or hypersensitivity to study intervention components or excipients.
  • Has any evidence of current interstitial lung disease or non-infectious pneumonitis or a prior history of interstitial lung disease (ILD) or non-infectious pneumonitis requiring high dose steroids or suspected ILD/non-infectious pneumonitis that cannot be ruled out by imaging.
  • Has moderate to severe pulmonary disease or current clinically significant pulmonary compromise that, in the investigator's judgment, could jeopardize safety or study conduct.
  • Has clinically significant bleeding symptoms, bleeding tumors, or significant bleeding tendency within 1 month prior to first dose.
  • Known active infectious diseases requiring systemic treatment or known human immunodeficiency virus (HIV).
  • Has received any prior systemic anticancer treatment for the disease under study.
  • Has received any prior therapy with a Topoisomerase-1 (TOP1i), including antibody-drug conjugates that are effectively loaded as TOP1i, or treatment targeting B7-H3.
  • Has severe, uncontrolled, or active cardiovascular disorders.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Ris-Rez + atezolizumab

Ris-Rez will be administered.

Atezolizumab will be administered.

Aktiver Komparator: Etoposide, carboplatin, atezolizumab ± lurbinectedin

Participants will receive etoposide, carboplatin, atezolizumab with or without lurbinectedin.

Carboplatin will be administered.

Atezolizumab will be administered.

Etoposide will be administered.

Lurbinectedin will be administered.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Overall survival (OS)
Zeitfenster: Up to 50 months

OS is defined as the time from the date of randomization to the date of death due to any cause.

Up to 50 months
Progression-free survival (PFS) by Blinded independent central review (BICR) assessment
Zeitfenster: Up to 50 months

PFS is defined as the time from the date of randomization to the date of first documented objective tumor progression per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by BICR assessment or death from any cause, whichever occurs first.

Up to 50 months

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Time to confirmed deterioration of disease-related symptoms and physical functioning
Zeitfenster: Up to 63 months

Time from the date of randomization to the first confirmed clinically meaningful deterioration in disease related symptoms and physical functioning using validated questionnaires will be measured.

Up to 63 months
Brain PFS
Zeitfenster: Up to 63 months

Brain PFS is defined as the time from the date of randomization to the date of first documented brain disease progression (PD) per modified Response assessment in neuro-oncology brain metastases (RANO-BM) by BICR assessment or death from any cause, whichever occurs first in participants with a presence of brain metastases at baseline.

Up to 63 months
PFS by Investigator Assessment
Zeitfenster: Up to 63 months

PFS is defined as the time from the date of randomization to the date of first documented PD per RECIST 1.1 by investigator assessment or death from any cause, whichever occurs first.

Up to 63 months
Objective response rate (ORR)
Zeitfenster: Up to 63 months

ORR is defined as the percentage of participants with best overall confirmed response of either complete response (CR) or partial response (PR) per RECIST 1.1 by RECIST-BICR assessment.

Up to 63 months
Duration of response (DOR)
Zeitfenster: Up to 63 months

DOR is defined as the time from the date of first documented objective response (CR or PR) that is subsequently confirmed per RECIST 1.1 by RECIST-BICR assessment to the date of first documented PD per RECIST 1.1 by BICR assessment or death due to any cause, whichever occurs first.

Up to 63 months
ORR for participants not receiving bridging cycle
Zeitfenster: Up to 63 months

ORR is defined as the percentage of participants with best overall confirmed response of either CR or PR per RECIST 1.1 by RECIST-BICR assessment

Up to 63 months
DOR for participants not receiving bridging cycle
Zeitfenster: Up to 63 months

DOR is defined as the time from the date of first documented objective response (CR or PR) that is subsequently confirmed per RECIST 1.1 by RECIST-BICR assessment to the date of first documented PD per RECIST 1.1 by BICR assessment or death due to any cause, whichever occurs first.

Up to 63 months
Participant reported experience on study treatment
Zeitfenster: Up to 63 months

Number of participants who reported their experience with study treatment using validated questionnaires will be measured.

Up to 63 months
Time to worsening of participants overall quality of life
Zeitfenster: Up to 63 months

Time from the date of randomization to the first confirmed clinically meaningful deterioration in overall quality of life using validated questionnaires will be measured.

Up to 63 months
Number of participants with adverse events (AEs), serious adverse events (SAEs), adverse events of special interest (AESIs) by severity
Zeitfenster: Up to 63 months
Up to 63 months
Number of participants with AEs leading to dose modifications or study intervention discontinuation
Zeitfenster: Up to 63 months
Up to 63 months
Number of participants with changes in hematology parameters
Zeitfenster: Up to 63 months
Up to 63 months
Observed pharmacokinetic concentration of Ris-Rez
Zeitfenster: Up to 63 months
Up to 63 months
Number of participants with Antidrug antibody (ADA) and Neutralizing Antibody (NAb) against Ris-Rez
Zeitfenster: Up to 63 months
Up to 63 months
Titres of ADA against Ris-Rez
Zeitfenster: Up to 63 months
Up to 63 months

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Studienleiter: GSK Clinical Trials, GlaxoSmithKline

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

25. Dezember 2026

Primärer Abschluss (Geschätzt)

24. Februar 2031

Studienabschluss (Geschätzt)

24. März 2032

Studienanmeldedaten

Zuerst eingereicht

12. November 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

12. November 2026

Zuerst gepostet (Tatsächlich)

18. November 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

18. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

12. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • 300599
  • 2026-527806-19 (Andere Kennung: EU CT Number)

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf

IPD-Sharing-Zeitrahmen

Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

IPD-Sharing-Zugriffskriterien

Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

Art der unterstützenden IPD-Freigabeinformationen

  • STUDIENPROTOKOLL
  • SAFT
  • ICF
  • CSR

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .